Medication Non-Adherence Autoimmune Liver Diseases
Over-the-Counter Medication Use Linked to Lower Adherence in Autoimmune Liver Disease
Table of Contents
Patients with autoimmune liver diseases – including autoimmune hepatitis (AIH),primary biliary cholangitis (PBC),and primary sclerosing cholangitis (PSC) – frequently use over-the-counter (OTC) medications,and this practice is associated with reduced adherence to prescribed treatments,according to a recent study published in United European Gastroenterology Journal. the findings highlight the importance of proactively assessing patient adherence and understanding attitudes toward conventional therapies.
Study Highlights & Key Findings
researchers surveyed over 1,100 patients with AIH, PBC, or PSC to assess OTC medication use and treatment adherence. Here’s a breakdown of the key takeaways:
Prevalence of OTC Use: Approximately 24.7% of patients reported using OTC medications. The highest prevalence was observed in those with PSC (28.3%), followed by PBC (25.2%) and AIH (22.1%). This suggests a significant proportion of patients are seeking additional, self-managed therapies alongside their prescribed regimens.
Adherence Rates Vary: Non-adherence – defined as skipping medication at least once weekly or self-initiating a dose reduction or discontinuation – was highest among patients with AIH (47%), followed by PSC (38%) and PBC (29%). These rates underscore the challenges in maintaining consistent treatment in these chronic conditions. OTC Use & Non-Adherence Linked: A statistically significant negative association was found between OTC medication use and treatment adherence across all patient groups (Odds Ratio [OR] 0.50; 95% confidence Interval [CI], 0.36-0.68). this association was especially strong in patients with AIH (OR 0.48; 95% CI, 0.29-0.80). This suggests patients using OTC medications are less likely to consistently take their prescribed medications.
Medication-Specific Adherence Patterns: Among AIH patients, treatment with steroids was associated with reduced adherence (OR 0.52; 95% CI, 0.32-0.84), while azathioprine did not show the same effect. Conversely, ursodeoxycholic acid (UDCA) treatment was linked to increased adherence in both PBC (OR 3.0; 95% CI, 0.66-12.8) and PSC (OR 5.2; 95% CI, 1.4-20.8) patients.These findings suggest specific medications may influence a patient’s willingness to adhere to their overall treatment plan.
Implications for Clinical Practice
The study’s authors emphasize the critical need for routine adherence assessments as an integral part of managing autoimmune liver diseases.
“Our data strongly supports the need for the careful assessment of patient adherence as an essential part of routine medical management,” the authors wrote. “Physicians should recognize skeptical patient attitudes toward conservative therapy and focus on the use of alternative medicines by their patients.”
This means clinicians should proactively:
Inquire about OTC Medication Use: Specifically ask patients about all medications they are taking, including those purchased without a prescription. Don’t assume patients will volunteer this information.
Explore Patient Beliefs & Attitudes: Understand why patients are using OTC medications. Are they seeking symptom relief, concerned about side effects of prescribed medications, or distrustful of conventional treatment?
Address Misconceptions: Provide clear and accurate information about the benefits and risks of both prescribed and OTC medications. Discuss potential interactions.
Tailor Treatment Plans: Consider patient preferences and concerns when developing treatment plans. Shared decision-making can improve adherence.
Monitor Adherence Regularly: Implement strategies to monitor adherence, such as pill counts, medication diaries, or electronic monitoring systems.
Understanding Autoimmune Liver Diseases
Autoimmune liver diseases are chronic conditions where the body’s immune system mistakenly attacks the liver.
Autoimmune Hepatitis (AIH): Characterized by inflammation of the liver caused by the immune system. Often treated with immunosuppressants like steroids and azathioprine.
* primary Biliary cholangitis (PBC): A chronic disease that slowly destroys the small bile ducts in the liver. Ursodeoxycholic acid (UDCA) is a mainstay of treatment.